15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Integra LifeSciences Holdings, 0 rate it Buy or better, 5 sit at Hold, and 1 rate it Sell or worse, a hold consensus. Targets span $13.00 to $19.00, a moderate spread. The average target of $17.00 sits 14% below the current $19.74. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.56 next quarter toward $2.62 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Hold
Strong Buy00%
Buy00%
Hold583%
Sell117%
Strong Sell00%
Based on 6 analysts giving stock ratings to Integra LifeSciences Holdings.
As of Jul, 0 of 6 firms rate IART a Buy (5 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
IART EPS & revenue forecast
EPS · NEXT QUARTER
$0.56
Range $0.49 – $0.60 · 10 analysts · +4% YoY
Next period, 10 analysts expect Integra LifeSciences Holdings to earn $0.56 a share (range $0.49 – $0.60), versus $0.54 a year earlier. Full-year consensus is $2.45, growing to $2.62 the year after.
REVENUE · NEXT QUARTER
$417.8M
Range $410.8M – $422.1M · 10 analysts · +4% YoY
Revenue is expected to reach $417.8M (range $410.8M – $422.1M), +3.9% year-over-year. Full-year consensus is $1.7B, rising to $1.7B next year.
Top analysts covering Integra LifeSciences Holdings
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IART.
#1
David Turkaly
JMP Securities · Rank #276
Buy
$25.00+26.6% to target
Overall win rate
31%
+ Follow
#2
Joanne Wuensch
Citigroup
Hold
$19.00-3.7% to target
Coverage
—
+ Follow
#3
David Toung
Argus Research
Buy
$25.00+26.6% to target
Coverage
—
+ Follow
#4
Ryan Zimmerman
BTIG
Hold
No targeton IART
Coverage
—
+ Follow
#5
RM
Ravi Misra
Truist Securities
Hold
$19.00-3.7% to target
Coverage
—
+ Follow
IART stock forecast FAQ
What is IART's average 12-month price target?+
The 5 analysts with a live target average $17.00 for Integra LifeSciences Holdings over the next 12 months, ranging from a $19.00 high to a $13.00 low.
Is IART stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 6 analyst ratings, 0 are Buy or Strong Buy, 5 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for IART?+
The Street-high target is $19.00 (Truist Securities), and the Street-low is $13.00 (JP Morgan). The average of all 5 active targets is $17.00.
How many Wall Street analysts cover IART?+
6 analysts have an active rating on Integra LifeSciences Holdings, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering IART?+
Among analysts who currently cover IART, David Turkaly of JMP Securities has the strongest overall Quantellect track record (Rank #276). Their current call is Buy with a $25.00 target.
What is Integra LifeSciences Holdings's projected EPS for next quarter?+
The consensus estimate is $0.56 per share (range $0.49 – $0.60) across 10 analysts. Full-year EPS is projected at $2.45, rising to $2.62 the following year.
How much revenue is Integra LifeSciences Holdings expected to report next quarter?+
Consensus revenue is $417.8M (range $410.8M – $422.1M). Full-year revenue is projected at $1.7B, growing to $1.7B next year.
Have analysts been upgrading or downgrading IART lately?+
As of Jul, 0 of 6 firms rate IART a Buy (5 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IART calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
BMO Capital
